SCHEDULE: FMR LLC Discloses 6.3% Stake in Olema Pharmaceuticals

FMR LLC and Abigail P. Johnson have reported a 6.3% beneficial ownership stake in Olema Pharmaceuticals Inc. common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, through various entities, beneficially own 5,023,092.35 shares of Olema Pharmaceuticals Inc. common stock.
• This ownership represents 6.3% of the total outstanding common stock of Olema Pharmaceuticals Inc.
• FMR LLC holds sole voting power over 5,015,265.00 shares and sole dispositive power over 5,023,092.35 shares.
• Abigail P. Johnson holds sole dispositive power over 5,023,092.35 shares, with no sole or shared voting power directly.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema Pharmaceuticals Inc.
• Key FMR LLC subsidiaries involved in the beneficial ownership include FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Strategic Advisers LLC, with Fidelity Management & Research Company LLC beneficially owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a substantial stake by a reputable asset manager like FMR LLC can signal confidence in Olema Pharmaceuticals Inc.'s long-term prospects, though it's a passive investment disclosure.

Positives

• Significant institutional investment from FMR LLC, a major asset manager, indicates confidence in Olema Pharmaceuticals Inc.'s long-term prospects.
• A 6.3% stake suggests a notable long-term position by a sophisticated investor, potentially signaling market validation for Olema Pharmaceuticals Inc.

Industry Context

StockSavvy.ai notes that significant institutional ownership by a firm like FMR LLC (Fidelity) in a biotechnology company like Olema Pharmaceuticals Inc. can be viewed positively by the market. It suggests that a major player with extensive research capabilities sees value and potential in Olema's pipeline or strategic direction, which is common in the often volatile and capital-intensive pharmaceutical and biotech sectors.

Comparison to Industry Standards

• A 6.3% stake by a major asset manager like FMR LLC is a substantial position, often signaling a long-term investment thesis. For comparison, similar stakes by large institutional investors in other emerging biotech firms (e.g., BlackRock's 5%+ stake in smaller biotechs or Vanguard's passive index-driven holdings) are common and generally interpreted as a vote of confidence in the company's fundamentals or market segment.
• While not a direct comparison to specific projects or results, the presence of a top-tier institutional investor like Fidelity, known for its rigorous due diligence, can differentiate Olema from other smaller biotech companies that may struggle to attract such significant institutional backing.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased confidence due to significant institutional backing from FMR LLC, potentially leading to greater stability or interest in the stock.
• Potential Investors: The presence of a major institutional investor like FMR LLC can attract other institutional and retail investors, validating Olema Pharmaceuticals Inc. as an investment.

Key Dates

Recommendation

The disclosure of a significant 6.3% stake by FMR LLC in Olema Pharmaceuticals Inc. is a positive signal, indicating institutional confidence. However, a Schedule 13G filing primarily reports ownership and does not provide new operational or financial performance data. While it suggests a favorable long-term view from a major investor, it doesn't offer immediate catalysts for a 'buy' recommendation without further fundamental analysis of Olema's business. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal while awaiting more comprehensive company-specific updates.

Keywords

Olema Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Pharmaceuticals, Fidelity